Background
Helicobacter pylori infection affects ~ 50% of the world’s population and has been recognized as one of the most common chronic infections in human. [
1] The overall prevalence is high in developing countries.
H. pylori infection cause upper gastrointestinal diseases including gastritis, peptic ulcer disease and also increase the risk of gastric cancer. Interestingly, several studies suggest that
H. pylori infection may influence the gut microbiome [
2‐
4]. Further, diverse extragastric diseases have been linked to
H. pylori infection, including dyslipidemia [
5], type 2 diabetes [
6], insulin resistance [
7] and metabolic syndrome [
8]. The correlation of
H. pylori infection and bilirubin levels has not been reported. Nevertheless,
H. pylori infection appears to play an important role in the development of metabolic disorders in which require further investigations.
In the current study, we aimed to investigate additional metabolic parameters and their clinical impact with regard to H. pylori infection in a Chinese population.
Methods
Study design and population
We performed a case-control study by selecting subjects who were overtly positive for H. pylori as cases and overtly negative controls matched by sex and age. We screened subjects aged 18–79 years who were receiving annual health examinations including 13C –urea breath test (UBT) in Beijing Tongren Hospital from March 2016 to May 2017. Subjects with 13C-UBT values≥10‰ or ≤ 1‰ were defined as overtly positive (cases) or overtly negative (controls) for H. pylori, respectively. Subjects with 13C-UBT results between 1‰ and 10‰ were excluded from the study. Subjects in the H. pylori positive group were matched 1:1 with age and sex to H. pylori negative individuals. After the primary assessment of the baseline characters for all subjects, we further excluded participants with liver and gall bladder diseases (hepatitis, jaundice, cholecystitis, biliary calculus), abnormal liver function (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 1.5 times upper normal limit, or bilirubin > twice upper normal limit), abnormal kidney function (Cr > upper normal limit) to better eliminate the potential biases caused by diseases.
Anthropometric and laboratory measurements
Each subject had anthropometric measurements. Presence of systematic or previous diseases, such as diabetes mellitus (DM), hypertension, hepatitis, jaundice, cholecystitis or biliary calculus were noted. Body mass index (BMI) was measured as weight (kg) divided by height (meters) squared (kg/m
2). Waist circumference (WC) was measured at the level of the umbilicus in cm. Blood pressure (BP) was measured three times when participants were seated, and the average of the last two measurements was recorded. Blood samples were collected after an overnight fasting for the determination of plasma glucose, glycosylated hemoglobin A1c (HbA1c), total cholesterol (TC), triglycerides (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), direct bilirubin, total bilirubin, total bile acids, alkaline phosphatase (ALP), ALT, AST [
9], γ-glutamyl transpeptidase (γ-GT), blood urea nitrogen [
10], serum creatinine (SCr) and uric acids (UA) concentrations.
Statistical analysis
Data are presented as the mean ± SD. The baseline characteristics of subjects were compared using the chi-squared test for categorical variables and the Student t-test for continuous variables. Distribution of discrete/qualitative variables was compared by trend chi-square test. Binary logistic regression analysis was used to estimate crude and adjusted odds ratios (ORs) (95% CIs) to assess the risk of bilirubin change associated with H. pylori infection. When data were not normally distributed, the correlations of bilirubin and cholesterol were determined by the Spearman correlation coefficient analysis. Calculations were performed using SPSS 24.0 statistical software (SPSS Inc., Chicago, IL, USA), and significance was established at a two-tailed P < 0.05.
Discussion
With the sensitivity and specificity exceeding 90%, UBT is often considered as the gold standard test in the diagnosis of
H. pylori infection [
17‐
19]. However, there is a “grey zone” of uncertainty when UBT values range from 2.0 to 5.0‰ [
20,
21]. Fortunately, positive and negative UBT results tend to cluster outside this range [
22]. We performed this study by selecting subjects at the extreme ends of the range of
13C-UBT values to comprise the study groups. We selected subjects with
13C-UBT values ≤1 ‰ and ≥ 10 ‰ to avoid false-positive and false-negative results.
In this case-control study, we found that subjects with high
13C-UBT values had lower bilirubin concentrations and less favourable lipid profiles compared those with low
13C-UBT values. In addition to being a breakdown product of heme, serum bilirubin is also a powerful antioxidant [
23,
24]. High normal concentrations of serum bilirubin correlate with better health outcomes [
11‐
16]. Bilirubin concentrations have been reported as being inversely associated with risk for cardiovascular disease [
15,
25], metabolic syndrome [
16], diabetes [
11], inflammatory disease [
13] and some cancers [
14]. However, little is known of determinants of bilirubin levels within the reference range. To our knowledge, this study indicates for the first time that
H. pylori infection may be associated with decreased bilirubin concentrations within the reference range.
H. pylori infection has been shown to result in chronic inflammation and influence of bile reflux [
9,
26], which may at least in part explain the bilirubin changes, but further research relating to possible mechanisms is required.
Our study also found an association between
H. pylori infection and lipid profiles. Serum LDL-C level was significantly higher and HDL-C significantly lower in
H. pylori infected subjects. This association was first observed in 1996 in Finnish subjects [
27]. Since then, several studies have been performed in different populations. However, the results are still equivocal. Most studies have supported the significant correlation between
H. pylori infection and elevated lipids levels [
5,
10,
28‐
33]. However Elizalde et al. found that
H. pylori infection had no influence on blood lipids in 686
H. pylori-positive patients before and 3 months after eradication therapy with a low treatment rate (53.6%) [
9]. It should be noted that cases and controls were not matched for sex and age which are key influence determinants of serum lipids. Furthermore
H. pylori infection is associated with a long-term effect on human health [
34] and 3 months may not be long enough to observe changes resulting from eradication of
H. pylori. In our relatively large study, we selected individuals with extreme
13C-UBT values to better distinguish the differences associated with
H. pylori infection and matched the subjects by sex and age. We found that
H. pylori infected subjects had significantly higher LDL-C and lower HDL-C levels.
Our study also found that decreased direct bilirubin was correlated with adverse lipid profiles, an important cause of cardiovascular disease and a feature of clusters of metabolic disease risk factors. Recent in vivo and in vitro studies suggest that this may due to bilirubin regulation of the fat burning nuclear receptor, PPAR-α and γ levels and thus inhibited lipid accumulation [
35,
36]. Given that
H. pylori infection may influence lipid profiles and that we could not prove a causal relationship between bilirubin and cholesterol levels. It is conceivable that the elevated cholesterol levels may be a result of both
H. pylori infection and decreased bilirubin concentrations.
Limitations of our study should be acknowledged. First, our study was not a prospective study, so we could not examine the effects of eradication therapy. Comparing bilirubin and lipid levels before and after eradication of H. pylori would enable more definitive conclusions. Second, our study was a cross-sectional study. Despite of statistical significance in lipid profiles between groups, we could not assure a real difference in clinical practice. Larger sample size prospective study is still required in the future.